When asked by Sen. Tammy Baldwin, D-Wis., who was specifically responsible for the grant terminations and delays at the NIH, ...

With billions of dollars of federal research funding cut since President Donald Trump began his second term, organizations ...

Cancer clinical trial specialist Sarah Cannon Research Institute is unifying its site management and contract research ...

Quest Diagnostics will work on a blood test for cancer risk that it says may help identify people who could benefit from more ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

Medtronic has named a new head of its acute care and monitoring division, tapping Kate Benedict to help lead the company’s ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

Keros Therapeutics’ pledge to hand $375 million to shareholders has not been enough to appease activist investor demands to ...

Hundreds of current and former staffers at the National Institutes of Health (NIH) are urging agency Director Jay ...

Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. | Axsome ...